Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

被引：7
|
作者：
Sorel, Nathalie
Roy, Lydia
Martineau, Geraldine
Guilhot, Francois
Turhan, Ali G.
Chomel, Jean-Claude
机构：
[1] CHU Poitiers, Lab Hematol, F-86021 Poitiers, France
[2] CHU Poitiers, EA 3805, F-86021 Poitiers, France
来源：
BLOOD | 2006年 / 108卷 / 05期
关键词：
D O I：
10.1182/blood-2006-03-011668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1782 / 1783
页数：2
相关论文
共 50 条
  • [21] Is resistance to imatinib still linked to the presence of a mutated bcr-abl allele in CML?
    Perot, Christine
    HEMATOLOGIE, 2006, 12 (04): : 225 - 225
  • [22] BCR-ABL kinase is dead; long live the CML stem cell
    Perl, Alexander
    Carroll, Martin
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (01): : 22 - 25
  • [23] Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
    Shah, Neil P.
    Skaggs, Brian J.
    Branford, Susan
    Hughes, Timothy P.
    Nicoll, John M.
    Paquette, Ronald L.
    Sawyers, Charles L.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (09): : 2562 - 2569
  • [24] IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING
    Sargas Simarro, C.
    Sanchez Perez, R.
    Llop Garcia, M.
    Ayala Diaz, R.
    Martinez Lopez, J.
    Regadera Gonzalez, A.
    Sanz Caballer, J.
    Mora Castera, E.
    Diaz Gonzalez, A.
    Cervera Zamora, J. V.
    Ibanez Company, M.
    Such Taboada, E.
    Liquori, A.
    Boluda Navarro, M.
    Gonzalez Romero, E.
    De Matteo, B.
    Sanz Alonso, M. A.
    Barragan Gonzalez, E.
    HAEMATOLOGICA, 2017, 102 : 165 - 165
  • [25] Leukemic stem cells of chronic phase CML patients possess uniquely elevated BCR-ABL kinase activity and acquire spontaneous BCR-ABL kinase domain mutations at a high frequency.
    Jiang, XY
    Saw, KM
    Eaves, A
    Eaves, C
    BLOOD, 2005, 106 (11) : 132A - 132A
  • [26] Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
    Agarwal, Anupriya
    Fleischman, Angela G.
    Petersen, Curtis L.
    MacKenzie, Ryan
    Luty, Samuel
    Loriaux, Marc
    Druker, Brian J.
    Woltjer, Randall L.
    Deininger, Michael W.
    BLOOD, 2012, 120 (13) : 2658 - 2668
  • [27] STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML
    Mauro, MJ
    Druker, BJ
    LEUKEMIA, 2001, 15 (03) : 488 - 488
  • [28] The ABL-kinase inhibitor STI571 causes BCR-ABL independent resistance in breast cancer cell lines.
    Burchert, A
    Jaenike, M
    Schmidt, M
    Brendel, C
    Rieder, H
    Neubauer, A
    BLOOD, 2001, 98 (11) : 255B - 255B
  • [29] A NOVEL AUTOMATED ASSAY FOR THE DETECTION OF BCR-ABL KINASE DOMAIN MUTATIONS
    Tanaka, R.
    Kimura, S.
    Hosomi, T.
    Hirai, M.
    Nagao, R.
    Takeuchi, M.
    Yao, H.
    Sakai, K.
    Hirai, H.
    Ashihara, E.
    Maekawa, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 352 - 352
  • [30] BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
    Akhilesh, S.
    Shah, Arunim
    Ashish, Ashish
    Singh, Nitish kumar
    Kaur, Manpreet
    Yadav, Abhay kumar
    Singh, Royana
    LEUKEMIA RESEARCH REPORTS, 2024, 21
12345